In conclusion, the results of this analysis suggest that in elderly patients with angina pectoris not controlled by conventional antianginal drugs, the addition of the metabolic agent ...

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug ...

The Calcium Channel Blockers Market was valued at US$ 14.5 Bn in 2022 and is projected to grow at a CAGR of 5.7% from 2023 to ...

Adding a newer anti-anginal drug to a calcium channel blocker:- What is the clinical and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium ...